Gap-134, a Connexin43 activator, prevents age-related development of ventricular fibrosis in Scn5a− mice

Justine Patin(Centre National de la Recherche Scientifique), Mickaël Derangeon(Centre National de la Recherche Scientifique), Agnès Hivonnait(Centre National de la Recherche Scientifique), Audrey Bihouée(Centre National de la Recherche Scientifique), Claire Castro(Harvard University), Isabelle Baró(Inserm), Hervé Le Marec(Centre National de la Recherche Scientifique), Jacques Lebreton(Centre National de la Recherche Scientifique), Agnès Tessier(Centre National de la Recherche Scientifique), Marja Steenman(Inserm), Flavien Charpentier(Inserm), Agnès Carcouët(Centre National de la Recherche Scientifique), Audrey Donnart(Centre National de la Recherche Scientifique)
Pharmacological Research
May 25, 2020
10.1016/j.phrs.2020.104922
Cited by 15

Related Papers

HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies
|Heart Rhythm|2011|1.5k
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death
|Nature|2003|961
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)
|EP Europace|2011|904
Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome
|Circulation|2010|850
Cardiac conduction defects associate with mutations in SCN5A
|Nature Genetics|1999|638